VNX 1012
Alternative Names: VNX-101-2Latest Information Update: 31 Mar 2025
At a glance
- Originator Vironexis Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Systemic lupus erythematosus
Most Recent Events
- 19 Mar 2025 Preclinical trials in Autoimmune disorders in USA (IV) (Vironexis Biotherapeutics, March 2025).
- 19 Mar 2025 Preclinical trials in Systemic lupus erythematosus in USA (IV) (Vironexis Biotherapeutics, March 2025).